Idexx Labs — Business Overview
What does IDEXX do?
IDEXX Laboratories is primarily a veterinary diagnostics company, with the vast majority of its business serving companion animal (pet) veterinarians. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX develops, manufactures, and distributes diagnostic instruments, consumable test supplies, laboratory services, and software for veterinary practices. It also has smaller businesses in water quality testing, livestock and dairy diagnostics, and human medical point-of-care diagnostics.
The company operates through three reportable segments, plus a smaller "Other" category:
| Segment | What it does |
|---|---|
| Companion Animal Group (CAG) | Diagnostic instruments, rapid test kits, reference laboratory services, practice management software, and imaging systems for pet (dog, cat) veterinarians |
| Water Quality Products (Water) | Microbial contamination testing products for drinking water, wastewater, recreational water, and bottled water |
| Livestock, Poultry and Dairy (LPD) | Disease screening tests for cattle, swine, and poultry; antibiotic residue detection in milk |
| Other | Human point-of-care analyzers measuring blood gases, electrolytes, and related parameters in hospitals and clinics |
CAG is by far the dominant segment, with Water and LPD playing supporting roles. IDEXX spent $251.2 million on R&D in 2025, equal to 5.8% of consolidated revenue, reflecting a consistent investment in new diagnostic innovations.
How does IDEXX make money?
IDEXX's core revenue engine is a classic "razor-and-blades" model: it places diagnostic instruments in veterinary clinics and then earns recurring revenue from the consumables those instruments require. Analyzers like the Catalyst One (chemistry) and ProCyte One (hematology) are sold or placed with practices, which then continuously purchase single-use slides, reagents, and test cartridges to run patient samples. This installed-base dynamic creates a predictable, repeat revenue stream that compounds as more instruments are placed globally.
Beyond consumables, IDEXX earns revenue from veterinary reference laboratory services, software subscriptions, and rapid assay test kits. Its network of approximately 80 reference laboratories worldwide handles samples sent in from clinics that need tests not available at the point of care. Software products like ezyVet, Cornerstone, and IDEXX Neo generate ongoing subscription or licensing fees from veterinary practices. Rapid assay SNAP test kits — single-use handheld tests for diseases like heartworm and Lyme disease — provide an additional consumable revenue stream, though canine vector-borne disease tests are seasonally weighted toward the first half of the fiscal year.
What market does IDEXX operate in?
The companion animal diagnostics market is the heart of IDEXX's business, and it benefits from powerful long-term growth tailwinds. Pet ownership has grown broadly across developed markets, and pet owners are increasingly willing to spend on veterinary care comparable to human healthcare. Veterinarians are correspondingly adopting more sophisticated diagnostics — a trend IDEXX actively accelerates by making testing easier, faster, and more integrated into clinic workflows.
The water testing and livestock/dairy markets are more mature and regulation-driven. Water testing products depend heavily on regulatory compliance requirements (such as U.S. EPA standards), which creates stable but slower-growing demand. LPD is tied to agricultural production cycles and government disease surveillance programs, making it less dynamic than the companion animal side.
Who are IDEXX's main competitors?
The companion animal diagnostics space has a handful of meaningful competitors, but IDEXX holds a strong position built on the breadth and integration of its product ecosystem. Key competitors in North America include Mars, Incorporated (through its Antech Diagnostics and Heska brands) and Zoetis Inc. (including its Abaxis subsidiary). Internationally, IDEXX also faces Fujifilm, Arkray, Mindray, and BioNote. In veterinary software, its largest competitor is Covetrus, Inc., which bundles software with animal health distribution.
IDEXX's stated competitive advantages center on integration, innovation, and switching costs. Its diagnostic instruments, reference laboratory services, software platforms (VetConnect PLUS, ezyVet, Cornerstone), and imaging systems are all designed to work together, creating a unified view of a patient's diagnostic history. This tight integration — combined with an AI-powered decision support tool (IDEXX DecisionIQ) and a large installed base — makes it operationally difficult for a practice to switch to a piecemeal alternative. The company also competes on the basis of diagnostic accuracy, speed of results, and the breadth of its test menu, including novel offerings like the IDEXX Cancer Dx Panel for canine lymphoma launched in 2025.
In water and LPD, IDEXX competes against smaller regional players and larger companies such as Neogen Corporation, Charm Sciences, Thermo Fisher Scientific, and BioChek. These segments are more fragmented and compete primarily on test accuracy, regulatory approval status, and ease of use.
Where does IDEXX operate?
IDEXX is a genuinely global business, with a direct sales presence across North America, Europe, Asia Pacific, Latin America, and Africa. Its approximately 11,000 employees are spread across roughly 34 countries. Reference laboratory services are offered in the U.S., Europe, Canada, Australia, Japan, New Zealand, South Africa, and South Korea, among other markets. Software products are sold primarily in North America, Europe, and Australia.
Manufacturing is concentrated in the United States and Europe. Primary production facilities are located in Westbrook, Maine (the company's headquarters and main manufacturing hub), Scarborough, Maine, Roswell, Georgia, and Memphis, Tennessee. Internationally, manufacturing and distribution facilities operate in the Netherlands, Switzerland, France, and the United Kingdom. The LPD manufacturing facility in Montpellier, France holds USDA approval to produce certain licensed products. Several of these facilities carry ISO 9001 quality certification.
IDEXX has some supply chain concentration risk worth noting. Certain critical consumables — including a significant portion of Catalyst chemistry slides — are sourced from a sole supplier, Ortho-Clinical Diagnostics, under agreements running through 2044. While IDEXX says supply has been uninterrupted, reliance on sole-source suppliers in key product lines is a structural vulnerability the filing explicitly flags as a risk.